BioCentury
ARTICLE | Company News

HHS awards $24.9M to Mapp

September 3, 2014 1:20 AM UTC

HHS's Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded Mapp Biopharmaceutical Inc. (San Diego, Calif.) a $24.9 million, 18-month contract for development and manufacturing of the company's ZMapp Ebola treatment. ASPR has the option to provide an additional $17.4 million.

HHS said ASPR's Biomedical Advanced Research and Development Authority (BARDA) will provide Mapp funds to produce enough ZMapp for both preclinical studies and early human safety trials, with a goal of FDA approval. Mapp could not be reached for comment. ...